|
|
|
Welcome to the Quality Counts. For those health conscious consumers and medical professionals that are looking to purchase nutritional supplements, vitamins, herbs, learning about medications, losing weight, health food, low carbs, high protein nutrition, and exercise, you have come to the right place. Quality Counts serves both the medical practitioner and consumer interested in nutritional therapy and alternative medicine.
Home > Health Conditions > Breast Cancer >
Aromasin (exemestane)
Aromasin (exemestane)
Related Topics:
News & Research:
-
Toxicity
of aromatase inhibitors may explain lack of overall survival improvement -
Science Daily, 8/22/11 - "compared to
tamoxifen, longer use of AIs was associated
with increased heart disease and bone fractures, but lower rates of blood clots
and cancer of the womb. There were no differences in the risk of stroke or other
types of cancer. Furthermore, use of AIs for 2-3 years after initial treatment
with tamoxifen was associated with a lower risk of death unrelated to breast
cancer compared to the use of either AIs or tamoxifen alone. The authors
therefore concluded that the toxicity of AIs when used for longer periods of
treatment may explain the lack of overall survival benefit while still having a
positive effect on breast cancer recurrence"
-
Exemestane reduces breast cancer in high-risk women, researchers show -
Science Daily, 6/4/11 - "The study showed that in postmenopausal women at
increased risk of breast cancer, but who have not previously been diagnosed with
breast cancer, the aromatase inhibitor called Aromasin, made by Pfizer, reduces
this risk by 65 percent compared with placebo" - Note: If you go the the
abstract is says "Funded by Pfizer and others" and like it says, Aromasin
(exemestane) is made by Pfizer. I've always thought of Aromasin
(exemestane) as being cheaper and less effective than Femara (letrozole) which
is made by Novartis. A good study would have included Femara. See
Femara (letrozole) at OffshoreRX.
-
Pain Makes Some End Breast Cancer Drug - WebMD, 9/6/07 -
"23% of the women in the new study given one of two
aromatase inhibitors -- Aromasin or Femara -- stopped taking their drugs due
to side effects, which also included hot flashes and nausea ... Forty-two
percent of the women reported serious bone and joint problems, such as
severe pain or difficulty opening a jar, and were referred for evaluation by
a rheumatologist"
-
Adjuvant Exemestane After Tamoxifen Improves Relapse- and Disease-Free
Survival - Doctor's Guide, 12/18/06
-
Aromasin May Cut Breast Cancer Return - WebMD, 12/15/06
-
Bone Loss Associated with Aromatase Inhibitor Therapy for Breast Cancer
Confirmed - Doctor's Guide, 6/4/06 -
"Aromatase inhibitor use was
associated with a relative risk (RR) ratio of 1.3"
-
Exemestane Becomes the First And Only Aromatase Inhibitor for Adjuvant
Sequential Therapy in Early-Stage Breast Cancer - Doctor's Guide,
5/17/06
-
Exemestane May Help Downgrade Tumours Scheduled for Mastectomy to
Breast-Conserving Surgery - Doctor's Guide, 3/27/06
-
Neoadjuvant Aromatase Inhibitors May Be as Effective as Chemotherapy in
Locally Advanced Breast Cancer - Doctor's Guide, 3/27/06
-
Fracture Rates Similar Between with Tamoxifen and Exemestane - Doctor's
Guide, 12/13/05
-
FDA Approves New Use for Breast Cancer Drug - WebMD, 10/6/05
-
FDA Approves Pfizer's Aromasin (Exemestane Tablets) for Adjuvant Treatment
of Early Breast Cancer in Postmenopausal Women - Doctor's Guide, 10/5/05
-
Exemestane in Treatment of Early Breast Cancer Leads to Significant Decrease
in Bone Mineral Density - Doctor's Guide, 5/20/05
-
Oral Aromatase Inhibitor, Exemestane, Improves Disease-Free Survival Over Tamoxifen - Doctor's Guide, 12/9/04
- Exemestane Reduces HDL Levels in Patients With Low Risk Early Breast Cancer - Doctor's Guide, 6/8/04
- Phase 3 Trial Shows Advantages of Exemestane Over Tamoxifen in Metastatic Breast Cancer - Doctor's Guide, 3/22/04
- Aromasin Beats Tamoxifen ... Again - WebMD, 3/19/04
- Exemestane Shows Advantage Over Tamoxifen for Metastatic Breast Cancer - Medscape, 3/19/04
-
New Drug Shows Promise Against Advanced Breast Cancer - HealthDay, 3/17/04
- Switch From Tamoxifen to Aromasin Lowers Recurrence Risk by 32% - WebMD, 3/10/04
- Exemestane After Tamoxifen May Improve Disease-Free Survival for Postmenopausal Women with Primary Breast Cancer Over Tamoxifen Alone - Doctor's Guide, 3/10/04
-
Drug [Exemestane] Gives One-Two Punch Against Breast Cancer - HealthDay, 3/10/04
- New Breast Cancer Drug Better Than Tamoxifen - Intelihealth, 3/10/04
Related Searches:
70521
|
